The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

The following is a summary of “Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) ...

Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

A new treatment at Unity Point Health is offering promising results for those with irregular heartbeats, otherwise known as ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

our research suggests that targeting NOX2 could offer a new treatment strategy to prevent or reduce the severity of irregular ...